RESUMO
Objective:To investigate the effect of outpatient cardiac rehabilitation on the quality of life and lifestyle changes in patients with coronary heart disease.Methods:A total of 135 patients with coronary heart disease who received exercise rehabilitation in the Cardiac Rehabilitation Center of Second Hospital of Shanxi Medical University were enrolled in the study. Among them, 63 cases seldom attended (≤12 sessions, low-attending group), 37 cases less frequently attended (13-24 sessions, medium-attending group) and 35 cases attended frequently (≥25 sessions, high-attending group). The clinical data, cardiac rehabilitation, Seattle Angina Scale (SAQ) score and SF-36 quality of life score before and after rehabilitation, and lifestyle changes such as out-of-hospital exercise were documented and compared among the three groups.Results:Compared with baseline, the 5-dimensional scores of SAQ and the 9-dimensional scores of SF-36 (except for role-emotional and health change) were not significantly improved after cardiac rehabilitation in low-attending group ( P>0.05), while the angina stability, angina frequency, treatment satisfaction of SAQ, and bodily pain, health change of SF-36 in medium-attending group were improved ( P<0.05), and both SAQ and SF-36 in high-attending group were increased ( P<0.05). After cardiac rehabilitation, the SAQ and SF-36 scores of patients in high-attending group were significantly higher than those of patients in low-attending group ( P<0.05). The lifestyle was changed in 77.14%(27/35)patients of high-attending group, which was higher and that of low-attending group(38.10%, 24/63) (χ 2=13.74, P<0.001). Conclusion:The outpatient exercise rehabilitation can improve the quality of life and change lifestyle of patients with coronary heart disease; and the effect of rehabilitation is associated with the attending frequency.
RESUMO
The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 800 laboratory-confirmed human infections, including 25 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS-CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. Therefore, CR3022 has the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g., m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, indicating that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD.
